Alliance for mRNA Medicines

What Alliance for mRNA Medicines does

Alliance for mRNA Medicines (AMM) is a Washington, D.C.-based nonprofit industry association founded in October 2023 by 31 member organizations to serve as the global advocacy and convening body for the mRNA and next-generation encoding RNA therapeutics and vaccines community. It represents a coalition that spans biopharmaceutical companies, academic and research institutions, CDMOs, and life science technology firms. AMM's mission is executed through four pillars: shaping U.S. and global policy that enables mRNA research to thrive, accelerating regulatory science, expanding patient access to mRNA medicines, and enabling manufacturing scale-up. Headquartered at 601 New Jersey Avenue, NW Suite 350, the organization maintains a staff in the 51-100 range and is led by Executive Director Clay Alspach and Board Chairman Andy Geall (Chief Development Officer of Replicate Bioscience).

AMM's offerings are non-commercial and centered on industry convening, scientific programming, policy advocacy, and public education rather than proprietary technology or products. Core programs include the annual ASCENT meeting (2nd edition scheduled October 28-30, 2026, in Coronado, CA, with partneringONE 1-on-1 meeting infrastructure), specialized scientific workshops (e.g., the April 2026 End-To-End Analytical Solutions for mRNA Therapeutics workshop co-hosted with the U.S. Pharmacopeia), policy submissions to FDA, webinars, and educational resources for policymakers, healthcare professionals, and the public. AMM also publishes original research, including a 2025 industry survey of 106 senior leaders and an RNA Journal manuscript addressing mRNA misconceptions (March 2026). The organization's technology footprint is informational rather than technical: a website, data portal, LinkedIn presence, email newsletter, and digital educational resources.

AMM operates as a 501(c)(6)-type membership-based industry association. Revenue is generated through member dues and event sponsorships, with ASCENT 2026 offering platinum (Aldevron), gold (Moderna, Wacker, Samyang Biopharm, and others), silver, and bronze tiers. Named member and sponsor organizations include Moderna, BioNTech, Pfizer, Aldevron, Replicate Bioscience, Wacker, Samyang Biopharm, Franklin Biolabs, Integrated DNA Technologies, Acuitas Therapeutics, and Danaher, alongside academic and research institutions such as Houston Methodist Research Institute and Johns Hopkins Bloomberg Center. AMM has no parent company and operates independently under a board governance structure.

Name

Alliance for mRNA Medicines

Legal name

Alliance for mRNA Medicines

Website

https://mrnamedicines.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Alliance for mRNA Medicines (AMM) is a Washington, D.C.-based nonprofit industry association founded in 2023 that convenes and represents the global mRNA medicines community — biopharmaceutical companies, academic institutions, and CDMOs — through policy advocacy, scientific programming, and events such as the annual ASCENT meeting.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Industry Association

NAICS

Business Associations (813910), Professional Organizations (813920), Professional Organizations (81392)

SIC

Services-Membership Organizations (8600), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Global Immunization & Vaccine Access Alliances (HLAJAKAK)

akta.pro secondary industries

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF)

Keywords

• MRNA industry advocacy
• RNA therapeutics policy
• Biotech industry association
• Regulatory science engagement
• Membership convening organization

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Membership Dues: AMM operates as a membership-based industry organization. Companies and individuals join as members to gain access to networking, advocacy representation, scientific programming, and industry collaboration opportunities. Membership fees likely form a core revenue stream.
2. Event Sponsorships: AMM generates revenue through event sponsorships, with platinum, gold, silver, and bronze sponsorship tiers for ASCENT 2026 and other events. Sponsors include major industry players such as Aldevron (Platinum), Moderna (Gold), Wacker (Gold), Samyang Biopharm (Gold), and others.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Alliance for mRNA Medicines is a nonprofit industry association that convenes and represents the global mRNA medicines community. It delivers value through policy advocacy before the FDA, NIH, and Congress; scientific programming including the flagship ASCENT annual meeting and technical workshops; educational content and public awareness efforts to combat mRNA misinformation; and a resources and data portal aggregating industry studies. Membership dues and event sponsorships fund its activities.

Product overview

Alliance for mRNA Medicines (AMM) is an industry alliance/organization, not a software product company. It operates as a convening body and advocacy organization that advances mRNA research through events and programs (including the annual ASCENT meeting, Innovation Forum, and specialized workshops), policy advocacy, resources/data publication, and public education. The organization does not offer commercial products or technology platforms but rather serves as a coordinating and advocacy hub for the mRNA research community.

Differentiator

Problem solved

Functional benefit

Products and services

• AMM Events and Programs (ASCENT, Workshops, Webinars) Annual meeting, technical workshops, webinars, and educational forums bringing together mRNA industry leaders, researchers, investors, and policymakers for networking, scientific exchange, and partnering. Includes the partneringONE 1-on-1 meeting platform for senior executives.
• Policy and Advocacy Program Advocacy services that submit comments on FDA guidance frameworks, engage with Congress on mRNA-related legislation, oppose citizen petitions challenging mRNA vaccine approvals, and represent the mRNA industry before regulators. Delivered for AMM member companies and the broader mRNA ecosystem.
• Resources and Data Portal Online aggregator and publisher of mRNA studies, original industry research, and data resources, positioning AMM as the preeminent source of mRNA-related industry data.
• Educational Content and Public Awareness Curated educational content including fact sheets, Q&A documents, myth-debunking materials, and a published RNA Journal manuscript addressing mRNA misconceptions, targeted at policymakers, healthcare professionals, and the general public.

Quantifiable outcome

• mRNA innovation projected to cut healthcare costs and expand cures (88% of experts surveyed)
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered flagship/ major, major, notable and core.

• Society for RNA Therapeutics (SRT)flagship/ majorStrategic or Co-development Partner · 17 June 2026AMM and SRT announced collaboration to present ASCENT 2026, AMM's annual meeting. The partnership brings together the leading industry advocacy organization for mRNA medicines and the leading scientific society for RNA therapeutic development. AMM and SRT will jointly select speakers and topics for dedicated scientific sessions focused on 'translational research in RNA therapeutics' and 'innovation in RNA therapeutics and delivery'. A new poster session will also be launched.
• Franklin BiolabsmajorStrategic or Co-development Partner · 3 June 2026Franklin Biolabs of Philadelphia co-hosted the 'Building RNA Medicine Excellence' conference with AMM on June 3, 2026 at the Cira Center. The conference celebrated Nobel Prize winners Katalin Karikó and Drew Weissman and featured participation from Philadelphia's leading academic medical centers.
• U.S. Pharmacopeia (USP)majorStrategic or Co-development Partner · 14 April 2026AMM and USP co-hosted a two-day workshop on End-To-End Analytical Solutions for mRNA Therapeutics in April 2026. The workshop brought together leading scientists, industry innovators, and regulatory experts to advance analytical solutions supporting manufacturing, characterization, and quality control of mRNA therapeutics.
• Danaher (member companies involved in Baby KJ case)notableOthers · 13 November 2025AMM noted that Danaher, Aldevron, Integrated DNA Technologies, and Acuitas Therapeutics were all part of the Baby KJ team and helped advance the first personalized gene-editing therapy using mRNA-encoded base editor. These are AMM member companies.
• AldevronnotableOthers · 13 November 2025AMM member company that was part of the Baby KJ historic innovation - first patient to receive personalized gene-editing therapy for a rare metabolic disease using mRNA technology.
• Integrated DNA TechnologiesnotableOthers · 13 November 2025AMM member company that was part of the Baby KJ historic innovation - first patient to receive personalized gene-editing therapy for a rare metabolic disease using mRNA technology.
• Acuitas TherapeuticsnotableOthers · 13 November 2025AMM member company that was part of the Baby KJ historic innovation - first patient to receive personalized gene-editing therapy for a rare metabolic disease using mRNA technology.
• Johns Hopkins Bloomberg CenternotableStrategic or Co-development Partner · 13 November 2025Hosted AMM and Foundation for mRNA Medicines forum on combating mRNA misinformation in December 2024.
• Houston Methodist Research Institute (Center for RNA Therapeutics)notableStrategic or Co-development Partner · 13 November 2025Dr. John P. Cooke, Director of Center for RNA Therapeutics at Houston Methodist Research Institute, serves as President of Society for RNA Therapeutics - AMM's partner for ASCENT 2026.
• Foundation for mRNA MedicinescoreStrategic or Co-development Partner · 5 December 2024AMM and the Foundation for mRNA Medicines co-hosted an educational forum at Johns Hopkins Bloomberg Center titled 'Don't Blame the Messenger(RNA): Combatting the Threat of Misinformation' to educate policymakers and the public about mRNA science and combat misinformation.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AdvaMed: AdvaMed is the leading U.S. medical technology industry association, engaging FDA and Congress on device and combination product regulation that intersects with mRNA delivery systems. It is a broader incumbent but overlaps with AMM on regulatory advocacy for advanced therapy manufacturers.
• Biotechnology Innovation Organization (BIO): BIO is the largest U.S. biotechnology trade association representing 1,000+ member companies across all therapeutic modalities. It is a broad incumbent that overlaps with AMM's advocacy on FDA policy, NIH funding, and Congressional engagement, though BIO's scope spans all of biotech rather than mRNA specifically.
• PhRMA: PhRMA is the leading U.S. pharmaceutical research and manufacturers association, representing large drug companies including several AMM members. It is a broad incumbent that engages Congress and FDA on policy issues overlapping with AMM, but its focus spans the full pharmaceutical industry rather than mRNA medicines specifically.
• American Association of Pharmaceutical Scientists (AAPS): AAPS is a professional society of pharmaceutical scientists covering drug development, manufacturing, and analytical sciences relevant to mRNA therapeutics. It hosts meetings, publishes research, and engages on regulatory science topics that overlap with AMM's policy and convening work.
• Association for Accessible Medicines (AAM): AAM is the U.S. trade association for generic and biosimilar medicine manufacturers, engaging on FDA and policy issues. While its focus is generic/biosimilar rather than mRNA, it overlaps with AMM in being a Washington-based industry advocacy organization engaging FDA and Congress.

Direct peers

• Alliance for Regenerative Medicine (ARM): ARM is an international advocacy organization representing the cell, gene, and tissue-based therapies sector, including mRNA and gene-editing approaches. It engages regulators, payers, and policymakers and convenes industry via meetings and policy papers, making it a direct peer in modality-adjacent advocacy.
• Foundation for mRNA Medicines: The Foundation for mRNA Medicines is a co-host of AMM's educational forums (e.g., the December 2024 misinformation event at Johns Hopkins). It operates as a closely allied foundation focused on public education and policy support for mRNA science, making it the most direct peer in mission and overlap.
• American Society of Gene & Cell Therapy (ASGCT): ASGCT is a professional society dedicated to gene and cell therapy, including mRNA-based and gene-editing modalities that overlap with AMM's advocacy. It convenes researchers, clinicians, and industry, and engages FDA on relevant guidance, making it a direct peer in scientific and policy convening.
• Society for RNA Therapeutics (SRT): SRT is a scientific society dedicated to RNA therapeutics development and is AMM's announced partner for co-presenting ASCENT 2026. Both organizations share the RNA medicines mission, with AMM focused on industry advocacy and SRT on scientific exchange, making them the closest direct peer in mission alignment.

Others

• CASSS: CASSS is a scientific community for separation science and biotechnology, including mRNA analytical and CMC topics. It hosts technical workshops and symposia relevant to AMM's analytical and manufacturing focus, making it an enabling peer in scientific programming rather than a direct competitor.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alliance-for-mrna-medicines
• Xx.com/mRNAAlliance

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alliance for mRNA Medicines